Pro-Dex (NASDAQ:PDEX) Raised to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Pro-Dex (NASDAQ:PDEX) from a buy rating to a strong-buy rating in a research report sent to investors on Monday.

Pro-Dex Stock Up 4.5 %

Shares of NASDAQ:PDEX opened at $18.70 on Monday. The stock’s 50-day moving average is $17.87 and its 200 day moving average is $18.10. The company has a market cap of $63.94 million, a PE ratio of 32.24 and a beta of 0.55. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.45 and a quick ratio of 2.08. Pro-Dex has a 1 year low of $14.51 and a 1 year high of $22.99.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $0.14 earnings per share for the quarter. The firm had revenue of $12.59 million for the quarter. Pro-Dex had a return on equity of 6.50% and a net margin of 4.13%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pro-Dex stock. Punch & Associates Investment Management Inc. lifted its stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX) by 8.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,610 shares of the medical instruments supplier’s stock after buying an additional 5,235 shares during the quarter. Punch & Associates Investment Management Inc. owned about 1.96% of Pro-Dex worth $1,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.